Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 1688 results for carers

  1. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development [GID-TA11404] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    Awaiting development [GID-TA11367] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Awaiting development [GID-TA11406] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  6. Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure

    Awaiting development [GID-IPG10404] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  7. In-situ Normothermic Regional Perfusion system for DCD donors

    Awaiting development [GID-IPG10405] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  8. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    Awaiting development [GID-TA11116] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development [GID-TA11342] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448

    Awaiting development [GID-TA11564] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    Awaiting development [GID-TA11516] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  14. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection